质子偶联叶酸转运体在间皮瘤培美曲塞耐药中的作用:临床证据与新药理学工具
研究探讨还原型叶酸载体(RFC/SLC19A1)和质子偶联叶酸转运体(PCFT/SLC46A1)在间皮瘤抗叶酸耐药中的作用。在两个培美曲塞治疗患者队列中,低PCFT与较低疾病控制率和较短总生存期相关,PCFT沉默降低培美曲塞敏感性,而5-氮杂-2'-脱氧胞苷可克服耐药。
要点
- 低PCFT患者疾病控制率显著较低,总生存期较短。
- PCFT联合TS低表达/高表达分层可识别预后最差患者。
- PCFT启动子甲基化可能是克服培美曲塞耐药的靶点。
核心结论
- 首次将PCFT确定为间皮瘤新型预后生物标志物,并提示靶向PCFT启动子甲基化可能清除低PCFT表达的培美曲塞耐药细胞。
研究设计与样本
- 在兩個培美曲塞治疗患者队列(测试队列N=73,验证队列N=51)中,用定量RT-PCR检测冻存组织PCFT、RFC和TS RNA水平,用组织微阵列免疫组化检测PCFT蛋白水平。
- 在间皮瘤细胞和球体中,通过5-氮杂-2'-脱氧胞苷介导的去甲基化和siRNA敲低评估PCFT表达和PCFT启动子甲基化对培美曲塞活性的贡献。
主要发现
- 测试队列中低PCFT患者总生存期11.3个月 vs 20.1个月(P=0.01),验证队列中12.6个月 vs 30.3个月(P=0.02),低PCFT均与较短总生存期相关。
- 低PCFT蛋白水平也与较短总生存期相关。
- 低PCFT且高TS患者预后最差,总生存期5.5个月。
- RFC与预后无关联,未接受培美曲塞治疗的患者中亦未发现关联。
- PCFT沉默降低培美曲塞敏感性,5-氮杂-2'-脱氧胞苷可克服耐药。
关键数值与推荐
- 低PCFT患者疾病控制率显著较低。
- 多因素分析证实PCFT的独立预后作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. PATIENTS AND METHODS: PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2'-deoxycytidine-mediated demethylation and siRNA-knockdown. RESULTS: Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N = 73, 11.3 versus 20.1 months, P = 0.01) and validation (N = 51, 12.6 versus 30.3 months, P = 0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5 months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2'-deoxycytidine overcame resistance. CONCLUSIONS: These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.
引用
- Giovannetti E, Zucali PA, Assaraf YG, et al. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol. 2017. PMID: 28945836. doi:10.1093/annonc/mdx499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。